Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Active Biotech focus on pharmaceutical development Completed divestment of SBL Vaccin - capital gain for the Group of SEK 190 million (Parent Company, SEK 150). Cash injection of just over half a...
-
Active Biotech focus on pharmaceutical development Completed divestment of SBL Vaccin - capital gain for the Group of SEK 190 million (Parent Company, SEK 150). Cash injection of just over half a...
-
Active Biotech koncentrerar på läkemedelsutveckling Försäljning av SBL Vaccin genomförd, reavinst i koncernen 190 Mkr (moderbolaget 150 Mkr). Kassan ökar med drygt en halv miljard kronor Framgångar...
-
Active Biotech koncentrerar på läkemedelsutveckling Försäljning av SBL Vaccin genomförd, reavinst i koncernen 190 Mkr (moderbolaget 150 Mkr). Kassan ökar med drygt en halv miljard kronor Framgångar...
-
Active Biotech has signed a Letter of Intent with the UK based company Avidex Ltd, Oxon, regarding the evaluation of a series of CD80 inhibitors (substances that can alter the immune response)...
-
Active Biotech har tecknat ett optionsavtal med Avidex Ltd., Oxon, England. Avtalet innebär att Avidex ska utvärdera en serie CD80-hämmare (substanser som påverkar kroppens immunförsvar), framtagna av...
-
For release content, please refer to the attachment....
-
For release content, please refer to the attachment....
-
For release content, please refer to the attachment....
-
Swedish Biotechnology Company, Active Biotech AB (Stockholm: ACTI), has concluded an agreement to sell its vaccines business, SBL Vaccin (SBL), to the UK leading vaccines company, PowderJect...